Fake news. Wrong place to look at. Here is the evidence.
Remestemcel-L is application to Center for Biologics Evaluation and Research (CBER).
https://www.fda.gov/media/141131/download
The page "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=report.page" is for Center for Drug Evaluation and Research (CDER).
If you click on search this month you will find this line:
"Drug Approval Reports by MonthSelect a Report:Reports include only BLAs/NDAs/ANDAs or supplements to those applications approved by the Center for Drug Evaluation and Research (CDER) and tentative NDA/ANDA approvals in CDER. The reports do not include applications or supplements approved by the Center for Biologics Evaluation and Research (CBER)."
https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2020-biological-device-application-approvals is the latest CBER approvals.
- Forums
- ASX - By Stock
- MSB officially rejected?
Fake news. Wrong place to look at. Here is the...
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.03 |
Change
-0.038(3.52%) |
Mkt cap ! $1.176B |
Open | High | Low | Value | Volume |
$1.08 | $1.09 | $1.03 | $5.993M | 5.748M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 117125 | $1.03 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 55682 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 13877 | 1.025 |
35 | 507067 | 1.020 |
15 | 137430 | 1.015 |
17 | 177972 | 1.010 |
17 | 625064 | 1.005 |
Price($) | Vol. | No. |
---|---|---|
1.030 | 49702 | 20 |
1.035 | 88221 | 18 |
1.040 | 140614 | 16 |
1.045 | 121178 | 22 |
1.050 | 79789 | 9 |
Last trade - 13.53pm 06/06/2024 (20 minute delay) ? |
|
|||||
Last
$1.03 |
  |
Change
-0.038 ( 3.65 %) |
|||
Open | High | Low | Volume | ||
$1.07 | $1.08 | $1.03 | 1390713 | ||
Last updated 14.12pm 06/06/2024 ? |
Featured News
MSB (ASX) Chart |